Original ArticlesMirtazapine Decreases the Pain Feeling in Healthy ParticipantsArnold, Pierre MD* †; Vuadens, Philippe MD* †; Kuntzer, Thierry MD†; Gobelet, Charles MD‡; Deriaz, Olivier MD, PhD§Author Information *Service de réadaptation neurologique ‡Service de réadaptation générale §Service de recherche, Clinique romande de réadaptation SuvaCare, Sion †Service de neurologie, CHUV, Lausanne, Switzerland Grants: The study was conducted without any grant. Conflict of interest: This study was not supported by funds external to the center. Reprints: Dr Pierre Arnold, Service de neuroréadaptation, Clinique romande de réadaptation SuvaCare, 1951 Sion, Switzerland (e-mail: [email protected]). Received for publication January 22, 2006; revised February 28, 2007; accepted August 29, 2007 The Clinical Journal of Pain: February 2008 - Volume 24 - Issue 2 - p 116-119 doi: 10.1097/AJP.0b013e318159f94a Buy Metrics Abstract Objectives The treatment of neuropathic pain is mainly based on antiepileptics, tricyclic antidepressants, and opiates. These drugs have important side effects disturbing the patient's quality of life. Mirtazapine (MTZ) is a new and well-tolerated tricyclic antidepressants with both monoaminergic and opioid properties that might favorably influence pain. The aim of this study was to assess whether MTZ can reduce the pain induced by a standardized stimulus presented to healthy human participants. The nociceptive flexion reflex (NFR) to an electric stimulus was chosen to determine the pain threshold. Methods The effect of MTZ compared to placebo was assessed on 10 healthy participants in a double-blinded cross-over design. The NFR was measured the day after a single oral dose of drug (30 mg) or placebo. Results A significant increase in upper limb (+29%, P=0.006) NFR threshold was observed. Discussion MTZ increases the pain tolerance in healthy participants. The potential benefit of this effect on pain should be investigated more thoroughly in chronic neuropathic pain patients. The NFR might serve as an additional tool for the monitoring of these patients. © 2008 Lippincott Williams & Wilkins, Inc.